New copper IUD shows promise in early trial

NCT ID NCT02446821

Completed Disease control Sponsor: Sebela Women's Health Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tested VeraCept, a copper intrauterine device (IUD), for long-acting contraception in 286 women aged 18-40. Researchers measured how well it prevents pregnancy and how easy it is to place. The results will help design a larger Phase 3 study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VeraCept copper intrauterine device (IUD)
What this could lead to: If successful, this could provide a new long-acting, hormone-free contraceptive option for women.
What could go wrong: This is an early Phase 2 study with only 286 participants, so results may not apply to everyone. IUDs carry risks like cramping, bleeding, or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONTRACEPTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONTRACEPTION

Contacts and locations

Locations

Advanced Research Associates

Corpus Christi, Texas, United States
Clinical Research of Philadelphia

Philadelphia, Pennsylvania, United States
Columbia University Medical Center

New York, New York, United States
Essential Access Health (formerly California Family Health Council)

Burbank, California, United States
Essential Access Health (formerly California Family Health Council)

Los Angeles, California, United States
Healthcare Clinical Data, Inc

Miami, Florida, United States
Oregon Health and Sciences University

Portland, Oregon, United States
University of California Davis Health System

Sacramento, California, United States
University of Cincinnati

Cincinnati, Ohio, United States
University of Colorado

Aurora, Colorado, United States
University of Pennsylvania

Philadelphia, Pennsylvania, United States
University of Utah

Salt Lake City, Utah, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.